Financial Data and Key Metrics Changes - In 2024, the company mined 170.6% Bitcoin, generating approximately $11 million in revenue and $3.9 million in core EBITDA, indicating strong growth compared to previous periods [11][10] - For Q4 2024, total revenue was approximately $2 million, down from $4.1 million in Q4 2023, primarily due to the April 2024 Bitcoin halving event [20][21] - The net income attributable to LM shareholders for Q4 2024 was $2 million, a significant improvement from a net loss of $1.6 million a year ago [22] - Core EBITDA for Q4 2024 increased to $3.3 million, nearly 10 times what was generated a year ago [23] Business Line Data and Key Metrics Changes - The company transitioned to a vertically integrated model, managing its own mining infrastructure, which has improved margins and reduced energy costs [7][9] - The acquisition of a 15 megawatt mining facility in Oklahoma marked a significant operational achievement [16] Market Data and Key Metrics Changes - The average Bitcoin price during Q4 2024 was approximately $83,000, while the average for the full year was about $61,000 [20] - As of February 25, 2025, the company expanded its total energized hash rate to 560 petahash per second and held 165.8% Bitcoin on its balance sheet [11] Company Strategy and Development Direction - The company plans to invest in next-generation mining hardware, energy efficiency initiatives, and strategic site acquisitions to support growth [14][26] - The focus remains on acquiring smaller power assets in the 5 to 20 megawatt range, which are often overlooked by larger operators [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating industry volatility and emphasized the importance of vertical integration and disciplined cost management for future success [25][13] - The company believes its current market cap presents a compelling value relative to its Bitcoin holdings, which are valued significantly higher than the market cap [12] Other Important Information - The company retained a portion of its mined Bitcoin to capture potential upside for shareholders and deepen alignment with the broader Bitcoin industry [10] - The combined cash and Bitcoin holdings increased by 200% in fiscal year 2024, with cash growing 40% to $3.4 million and Bitcoin holdings surging over 300% to $14 million [23] Q&A Session Summary Question: Current operating stats and new machines - The 256 new machines have not yet arrived and will be added once installed [31] Question: Open sockets and deployment of new machines - There is space to add about two more megawatts, and the new machines will replace less efficient ones [33][35] Question: Timeline for new containers - Groundwork for the new containers is expected to take about three weeks, with installation within 90 days [38] Question: Opportunities in Texas - The company has looked at several sites in Texas but currently has no outstanding letters of intent [40] Question: Deployment of Luxor OS2 - Luxor OS2 has been deployed on all machines at the Calumet mining site but not on those at core [42] Question: Details on the secured loan - The $5 million secured loan is primarily for the new mining site in Oklahoma, structured to avoid liquidating Bitcoin [45]

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $10.1 million, a decrease of 11.3% compared to the prior quarter and a decrease of 66.8% year-over-year due to lower product volumes [34] - GAAP gross loss was $4.3 million, or 42.5% of revenue, compared to a gross loss of $2.3 million, or 20.5% of revenue in the prior quarter [35] - GAAP net loss was $15.4 million, or $0.12 per diluted share, compared to a loss of $12.2 million, or $0.10 per diluted share in the prior quarter [37] - Adjusted EBITDA loss was $12.2 million, which was better than the midpoint of guidance, compared to losses of $10.5 million in the prior quarter [38] - The company ended the quarter with $8.3 million in cash on the balance sheet [39] Business Line Data and Key Metrics Changes - Over 70% of current purchase orders are in the 1P category, indicating a significant shift from previous quarters where 1P revenues were only 16% and 30% in Q2 and Q3 respectively [13] - The company has transitioned from a 2P only company to one that offers both 1P and 2P solutions, significantly increasing the total addressable market [15] Market Data and Key Metrics Changes - The company is seeing strong growth in the Northeast and Southwest U.S. markets, with opportunities expanding in the Southeast due to high wind product offerings [46] - The company has signed a multi-year supply agreement with Strata Clean Energy for at least 500 megawatts of 2P trackers, which could expand to over 1 gigawatt [28] Company Strategy and Development Direction - The company is focused on expanding its 1P product offerings, which now include high wind solutions and compatibility for various module types, to capture a larger market share [14] - The management believes that the company is poised to achieve quarterly profitability in 2025, driven by strong margins and a robust product cost structure [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the solar market's resilience, noting that solar has experienced growth regardless of political changes [48] - The company expects to see continued improvement in revenue, margin, and adjusted EBITDA in Q4, with a target of achieving adjusted EBITDA breakeven on a quarterly basis in 2025 [41] Other Important Information - The company entered into a binding term sheet for a $15 million promissory note, which is expected to close by the end of November [21] - The company received an additional $4.7 million in cash from an earn-out on a prior investment, improving its liquidity position [39] Q&A Session Summary Question: What proportion of the backlog is coming from 1P revenues? - Management indicated that about 70% of signed purchase orders are in the 1P category, with expectations for revenue growth from this segment [43] Question: How is the geographic distribution of projects? - The company has a diverse geographic focus, with strong growth in the Northeast, Southwest, and Southeast markets [46] Question: What is the breakeven revenue range? - Management confirmed that the breakeven revenue range remains at $50 million to $60 million, consistent with previous discussions [51] Question: What is the outlook for 2025 revenue guidance? - Management expects about 60% of the signed backlog to start recognizing revenue in 2025, indicating strong growth potential [53] Question: Will there be opportunities for 1P in the Strata supply agreement? - Currently, the agreement is for 2P delivery, but there are expectations for future opportunities to cross-sell between 1P and 2P products [54]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $15.8 million, a decline of $2.4 million or 13% year-over-year [24][6] - Lease revenue decreased by $3.5 million or 58% year-over-year in Q4, offsetting mid-teens growth in cash system sales [7][6] - Net loss attributable to stockholders for Q4 2024 was $8 million or $11.23 per share, compared to a net loss of $11.1 million or $20.14 per share for Q4 2023 [32] Business Line Data and Key Metrics Changes - Cash system sales in the U.S. increased by 27% year-over-year, representing 87% of total U.S. system sales in Q4 compared to 58% last year [8] - The percentage of total systems revenue from internal lease programs decreased from approximately 41% in the prior year to 20% in Q4 2024 [25] - Sales through distributors more than doubled year-over-year in Q4, particularly in the APAC and EMEA regions [12] Market Data and Key Metrics Changes - Revenue results in fiscal year 2024 reflected a decline of 15% year-over-year, which was better than many competitors [13] - The decline in total revenue was driven by a 13% decrease in both U.S. and international revenue [24][25] - Customer financing pressures and economic uncertainty continue to impact system adoption [10] Company Strategy and Development Direction - The company is focused on transitioning to cash system sales, aiming for 70% to 75% of total systems revenue to come from cash sales [26] - A strategic initiative to restructure debt obligations resulted in a 47% reduction in total debt from $74.9 million to approximately $39.7 million [17] - The company plans to launch a new body system in the second half of 2025, which is expected to drive growth [55] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that macroeconomic headwinds will continue to impact quarterly performance but remains optimistic about returning to growth [14][36] - The company is not providing full-year 2025 financial guidance but expects total revenue for Q1 2025 to be at least $14 million [36] - Management believes that the impact of strategic transitions is behind them, looking forward to a more normalized business profile [13][42] Other Important Information - A 1 for 11 reverse stock split was announced, with the company's common stock trading on an adjusted basis starting March 4, 2025 [21] - The company has made significant progress in reducing cash used in operations by 14% year-over-year [15] Q&A Session Summary Question: Can you characterize what a normal business profile is going forward? - Management indicated that while predicting the macroeconomic environment is challenging, they expect performance to improve compared to 2024 [42] Question: How is the Venus Hair business performing? - Management expressed satisfaction with the performance of the Venus Hair business, particularly the Venus ARTAS Robot, and noted ongoing R&D innovations [46][47] Question: What is the strategy for top-line growth in 2025? - Management highlighted the need to establish a normal rhythm of orders with new distribution partners and anticipates growth in international business [53][54] Question: Are there further cost-cutting measures available? - Management stated that the infrastructure is efficient, and the focus is on increasing sales rather than further cost reductions [57] Question: How do tariffs affect the business? - Management noted that products are manufactured in both the U.S. and Israel, and currently, they do not expect a substantial near-term impact from tariffs [60]

Westport Fuel Systems Inc (WPRT) Q4 2024 Earnings Conference Call March 31, 2025 01:30 PM ET Company Participants Ashley - Vice President of Investor RelationsConference Call Operator - OperatorConference Call Operator - OperatorConference Call Operator - OperatorDan Selis - Chief Executive Officer and DirectorBill Larkin - Chief Financial Officer Conference Call Participants Chris Dendrinos - Analyst, RBC Capital MarketsEric Stein - Analyst, Craig Hallam Capital GroupRob Brown - Analyst, Lake Street Capita ...

Chicago Atlantic BDC (LIEN) Q4 2024 Earnings Call March 31, 2025 01:07 PM ET Company Participants Tripp Sullivan - Investor Relations, SCR PartnersPeter Sack - CEOMartin Rodgers - CFODino Colonna - PresidentPablo Zuanic - Managing Partner Operator Good morning, and welcome to the Chicago Atlantic BDC Fourth Quarter twenty twenty four Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Tripp Sullivan of Inves ...

KULR Technology Group (KULR) Q4 2024 Earnings Call March 31, 2025 12:33 PM ET Company Participants Stuart Smith - OwnerMichael Mo - Chairman, CEO & PresidentShawn Canter - Chief Financial Officer Stuart Smith Good afternoon and thank you for joining us for the Cooler Technology Group fourth quarter and full year twenty twenty four earnings call. Joining me on the call today will be Michael Moe, the Chief Executive Officer of the company, as well as Sean Kanter, the Chief Financial Officer of the company. I ...

Ironwood Pharmaceuticals (IRWD) Q4 2024 Earnings Call March 31, 2025 12:02 PM ET Company Participants Greg Martini - CFOThomas McCourt - CEOMichael Shetzline - SVP, Chief Medical Officer and Head of Research & DevelopmentJason Butler - Managing Director & Biotechnology Equity ResearchKatherine Wang - Equity AssociateMatthew Cowper - Vice President - Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareDavid Amsellem - Sr. Research Analyst Operator My ...

Venus Concept Inc. (NASDAQ:VERO) Q4 2024 Earnings Conference Call March 31, 2025 8:00 AM ET Company Participants Rajiv De Silva - CEO Domenic Della Penna - EVP and CFO Conference Call Participants Marie Thibault - BTIG Jeremy Pearlman - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter and Fiscal Year 2024 Earnings Conference Call for Venus Concept Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being r ...

Financial Data and Key Metrics Changes - In the fourth quarter, net sales were $160 million, a decrease of $38 million or 19% compared to the same period in 2023, aligning with planned lower volumes [25] - New unit sales declined by 7% or approximately 92 units, while the average selling price for new units grew by 3% [24] - Pre-owned retail unit sales, including consigned vehicles, were down 23% or 268 units during the quarter [25] - SG&A expenses increased to $53 million for the quarter from $46 million in the prior year, primarily due to higher transaction and legal expenses related to restructuring [26] - Adjusted EBITDA loss was $24 million compared to a loss of $11 million in the prior year period [27] Business Line Data and Key Metrics Changes - On a same-store basis, there was a decline in both new and used unit volume, partially offset by improved gross profit per unit sold [15] - Total gross margin was 19% in the fourth quarter compared to 21% in the third quarter of 2024; excluding inventory and LIFO adjustments, gross margin was 23% [16] - Finance and Insurance (F&I) revenue was over $6,000 per unit, up 3% relative to the third quarter [16] Market Data and Key Metrics Changes - The company’s new inventory is comprised of 75% model year 2025 units and 25% prior model year units, with over 77% of new inventory being towable products [17] - Motorized inventory decreased by 44% from the prior year's period due to aggressive inventory management [18] Company Strategy and Development Direction - The company is focused on rightsizing its dealership portfolio to de-lever its balance sheet and improve earnings power [9] - A letter of intent has been signed to divest three locations, which will add cash to the balance sheet and reduce indebtedness [11] - The company aims to improve operational performance across all functional areas of its dealerships, including inventory, sales, service, F&I, and marketing [21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2024 was a year of significant transformation and that the company is executing a turnaround plan [7] - There is optimism that the company is near the bottom of a prolonged market down cycle, with expectations for future retail demand for RVs to return to historical levels [21] - Management expressed confidence in the company’s ability to drive improved results for stakeholders [27] Other Important Information - The company completed a comprehensive recapitalization, including a $30 million common equity investment and the exchange of convertible preferred stock for common stock [7] - The company reduced floor plan debt by $11 million and term loan debt by $6 million during the quarter [27] Q&A Session Summary - No questions were fielded following the prepared remarks, and the call concluded without a Q&A session [5][30]

Financial Data and Key Metrics Changes - Curis reported a net loss of $9.6 million or $1.25 per share for Q4 2024, compared to a net loss of $117 million or $2.03 per share for the same period in 2023 [19] - For the full year 2024, the net loss was $43.4 million or $6.88 per share, compared to a net loss of $47.4 million or $8.96 per share in 2023 [19] - Research and development expenses were $9 million for Q4 2024, down from $10 million in Q4 2023, primarily due to lower clinical and research costs [19][20] - General and administrative expenses decreased to $3.4 million in Q4 2024 from $4.9 million in Q4 2023, attributed to lower legal and consulting costs [20][21] Business Line Data and Key Metrics Changes - In the NHL segment, the TakeAim Lymphoma study is evaluating emavusertib in combination with ibrutinib, with positive feedback from EMA and FDA regarding potential accelerated approval pathways [6][12] - The study has 30 clinical sites open for enrollment, aiming to complete enrollment in the next 12 to 18 months [8][12] - In the AML segment, emavusertib showed a 38% composite CR rate in a study involving patients with FLT3 mutations, indicating strong efficacy compared to existing treatments [14][15] Market Data and Key Metrics Changes - The company has received Orphan Drug Designation for emavusertib in primary CNS lymphoma in both the U.S. and Europe, enhancing its market position [12] - The discussions with regulatory agencies indicate a favorable environment for potential approvals, as there are currently no approved treatments for primary CNS lymphoma [43] Company Strategy and Development Direction - The company is focused on accelerating the development timeline for emavusertib, with plans to enroll additional patients to support filings for accelerated approval [8][12] - There is an ongoing strategy to explore partnerships with major players in the NHL and AML spaces, indicating a proactive approach to enhance its market presence [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical data and the clarity received from regulatory agencies, which supports the company's development plans [12][42] - The company anticipates maintaining a cash runway into Q4 2025, with a quarterly burn rate of approximately $10 million [26][22] Other Important Information - The company completed a registered direct offering and private placement with net proceeds of approximately $10.8 million, extending its financial runway [21] - The company is currently conducting a Phase 1 study of emavusertib in combination with venetoclax and azacitidine for frontline AML, with ongoing enrollment [16][52] Q&A Session Summary Question: Can you talk about cash runway and expenses going forward? - Management confirmed a quarterly burn rate of about $10 million, extending the cash runway to Q4 2025 due to recent offerings [26] Question: Any potential inbound interest from partners? - Management indicated ongoing discussions with potential partners, given the promising data in NHL and AML [28] Question: How many patients have been dosed with emavusertib? - A total of 13 patients have been dosed at 100 mg BID in the study [35] Question: What does the EMA expect in terms of response rates? - Management noted that both agencies are supportive and expect compelling data, with a response rate above 25% being favorable [43] Question: How should we think about TakeAim Leukemia? - Management emphasized caution regarding data expectations in leukemia but highlighted ongoing studies and interest in monotherapy extensions [50][55]